Jazz Pharmaceuticals

8 hours ago · prnewswire.com

Presentations showcase Phase 3 ACTION trial progress and continued development of novel therapies for rare brain cancers For U.S. media and investors only DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that clinical and preclinical research from its neuro-oncology portfolio will be presented at the upcoming 2026 Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 12-15 in Philadelphia. Key highlights include: The confirmatory Phase 3 ACTION trial evaluating Modeyso® (dordaviprone), formerly ONC201, continues to advance.

5 days ago · fool.com

Jazz Pharmaceuticals' financial results are improving. The company's oncology business could push sales and earnings even higher.

7 days ago · zacks.com

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 days ago · prnewswire.com

Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months Mature HERIZON-GEA-01 results show Ziihera plus chemotherapy delivered statistically significant and clinically meaningful OS benefit, reducing the risk of death by 24% versus trastuzumab plus chemotherapy For U.S. media and investors only DUBLIN, Oct. 23, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without Tevimbra® (tislelizumab-jsgr), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results from the second interim, and final formal, analysis were presented as a late-breaking rapid oral presentation (LBA79) at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

14 days ago · prnewswire.com

DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.

17 days ago · zacks.com

Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks and earnings pressures.

18 days ago · seekingalpha.com

Jazz Pharmaceuticals is transforming beyond oxybate reliance, with diversified growth across sleep medicine, epilepsy, and oncology portfolios. JAZZ delivered robust Q2 2026 results: $1.21B revenue (+16% YoY), strong gross margins (92.1% non-GAAP), and raised FY guidance to $4.60–$4.75B. Ziihera's FDA approval for 1L HER2-positive GEA marks a major oncology expansion, with clinical data showing a significant survival benefit over standard of care.

27 days ago · zacks.com

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 month ago · marketbeat.com

Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.

1 month ago · marketbeat.com

Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Get Jazz Pharmaceuticals alerts:Sign UpZiihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically significant overall-survival result for its zanidatamab-plus-chemotherapy arm versus a control arm in a second interim analysis.